Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S908000
Reexamination Certificate
active
07105561
ABSTRACT:
A method of treating cancer is provided comprising administering an amount of etodolac to a subject afflicted with cancer that is effective to reduce the viability and/or to sensitize the cancer to an anti-cancer agent.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4337760 (1982-07-01), Rubin
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-09-01), Dell
patent: 4542013 (1985-09-01), Keith et al.
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka et al.
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5780435 (1998-07-01), Garnick et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5968974 (1999-10-01), Kargman et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 2002/0042375 (2002-04-01), Heimbrook et al.
patent: 2003/0004142 (2003-01-01), Prior et al.
patent: 2003/0004143 (2003-01-01), Prior et al.
patent: 2005/0239752 (2005-10-01), Carson et al.
patent: 1299577 (1992-04-01), None
patent: 2226340 (1973-03-01), None
patent: 0289262 (1986-11-01), None
patent: 1436893 (1976-05-01), None
patent: WO-96/28148 (1996-09-01), None
patent: WO-97/48391 (1997-12-01), None
patent: WO-98/09603 (1998-03-01), None
patent: WO-98/18490 (1998-05-01), None
patent: WO-98/40078 (1998-09-01), None
patent: WO-00/02555 (2000-01-01), None
patent: WO-00/13410 (2000-03-01), None
patent: WO-01/06990 (2001-02-01), None
patent: WO-02/02125 (2002-01-01), None
patent: WO-02/12188 (2002-02-01), None
Mycek et al, “Lippincott's Illustrated Reviews, Pharmacology, Second Edition”, Lippincott-Raven Publishers, pp. 373 and 387-395 (1997).
Chemical Abstracts 136:303669, “Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines”, Kamijo et al (2001).
The Merck Index, Eleventh Edition,Budavari, S., et al., (eds.), Merck & Co., Inc., Rahway, N.J., Entry No. 3831—“Etodolac”,(1989),p. 608.
In: Remington's Pharmaceutical Sciences, Eighteenth Edition,Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),pp. 1115-1121.
Abramson, S..B. ,et al. ,“The Mechanisms of Action of Nonsteroidal Antiinflamatory Drugs”,Arthritis&Rheumatism,32 (1), (Jan. 1989),pp. 1-9.
Alexanian, R..,et al. ,“The Treatment of Multiple Myeloma”,The New England Journal of Medicine,330 (7), (Feb. 17, 1994),pp. 484-489.
Barlogie, B.,et al. ,“Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.”,Blood,72, (1988),2015-2019.
Bataille, R.,et al. ,“Multiple Myeloma”,New England Journal of Medicine,336, (1997),1657-1664.
Becker-Scharfenkamp, U..,et al. ,“Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography,621 (2), (Nov. 24, 1993),pp. 199-207.
Bellosillo, B..,et al. ,“Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood,92 (4), (Aug. 15, 1998),pp. 1406-1414.
Berendes, U..,et al. ,“Simultaneous Determination of the Phase II Metabolites of the Non Steriodal Anti-inflammatory Drug Etodolac in Human Urine”,Enantiomer,1, Abstract Only, Chemical Abstracts, Abstract No. 126:207064q,(1996),415-422.
Brenna, E..,et al. ,“New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron,53, (1997), 17769-17780.
Brocks, D..R. ,et al. ,“Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics,26 (4), (1994),pp. 259-274.
Carson, D..A. ,et al. ,“Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine”,Proc. Natl. Acad. Sci. USA,89 (7), (Apr. 1992),pp. 2970-2974.
Chinetti, G..,et al. ,“Activation of Proliferator-activated Receptors alpha and Y Induces Apoptosis of Human Monocyte-derived Macrophages”,The Journal of Biological Chemistry,273 (40), (Oct. 2, 1998),pp. 25573-25580.
Cunningham, D.,et al. ,“High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology,12, (1994),764-768.
Demerson, C..A. ,et al. ,“Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids”,Journal of Medicinal Chemistry,19 (3), (1976),pp. 391-395.
Demerson, C..A. ,et al. ,“Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem.,26 (12), (Dec. 1983),pp. 1778-1780.
Drachenberg, D..F. ,et al. ,“Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology,18 (1), (Jan./Feb. 2000),pp. 37-44.
Duffy, C..P. ,et al. ,“Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)”,European Journal of Cancer,34 (8), (Jul. 1998),pp. 1250-1259.
Hahnfeld, L..E. ,et al. ,“Prostate Cancer”,The Medical Clinics of North America—The Aging Male Patient,83 (5), (Sep. 1999),pp. 1231-1245.
Harousseau, J..L. ,et al. ,“Double-Intensive Therapy in High-Risk Multiple Myeloma”,Blood,79 (11), (Jun. 1, 1992),pp. 2827-2833.
Krajewski, S..,et al. ,“Detection of Multiple Antigens on Western Blots”,Analytical Biochemistry,236 (2), Article No. 0160,(May 1996),pp. 221-228.
Landis, S..H. ,et al. ,“Cancer Statistics, 1998”,CA Cancer J. Clin.,48 (1), (1998),pp. 6-29.
Lee, D..H. ,“Proteasome Inhibitors: Valuable New Tools For Cell Biologists”,Trends in Cell Biology,8, (Oct. 1998),pp. 397-403.
Lehmann, J..M. ,et al. ,“Peroxisome Proliferator-activated Receptors alpha and Y Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs”,The Journal of Biological Chemistry,272 (6), (Feb. 7, 1997),pp. 3406-3410.
Leoni, L..M. ,et al. ,“Induction of an Apoptotic Program in Cell-Free Extracts by 2-Chloro-2′-deoxyadenosine 5′-triphosphate and Cytochrome C”,PNAS,USA, 95 (16), (Aug. 4, 1998),pp. 9567-9571.
Lochmuller, C..H. ,et al. ,“Chromatographic Resolution of Enantiomers—Selective Review”,Journal of Chromatography,113 (3), (Oct. 22, 1975),pp. 283-302.
Martel, R..R. ,et al. ,“Anti-inflammatory and Analgesic Properties of Etodolic Acid in Rats”,Canadian Journal of Physiology and Pharrmacology,54 (3), (Jun. 1976),pp. 245-248.
Mooney, P..T. ,et al. ,“Cell Pathways' Exisulind ‘Aptosyn’ Demonstrates Potential to Delay Hormonoe Therapy in Post-Prostat
Adachi Souchi
Carson Dennis A.
Cottam Howard B.
Leoni Lorenzo M.
Krass Frederick
Schwegman Lundberg Woessner & Kluth P.A.
The Regents of The University of California
LandOfFree
Use of etodolac for the treatment of prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of etodolac for the treatment of prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of etodolac for the treatment of prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3591307